Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

OrbiMed, a Life Sciences Investor, Raises $800 Million for Asia Partners IV

publication date: Mar 1, 2021

OrbiMed Advisors, a global life sciences investment firm, announced it has secured $3.5 billion in commitments for its latest capital raise, including $800 million for OrbiMed Asia Partners IV. The Asia Partners series of funds invests primarily in China and India, from venture capital through growth stage for biotech, pharma, medical device, diagnostic and healthcare companies. It plans to make investments that range in size from $10 million to $100 million in approximately 20 portfolio companies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital